MAGEA4 and head and neck squamous cell carcinoma: In 2020, Adaptimmune reported the ADP-A2M4 single-arm, phase II pilot trial of MAGE-A4 targeted, HLA-A*02:01 restricted TCR-T therapy in combination with pembrolizumab for first-line recurrent/metastatic, HPV-agnostic HNSCC.